Pegasus Laboratories, Inc., announced that under its registered trademark PRN® Pharmacal, KBroVet® (potassium bromide chewable tablets) has received full approval from the U.S. Food and Drug Administration for the control of seizures associated with idiopathic epilepsy in dogs. The fully approved product labeling is expected to transition in the marketplace beginning approximately April-May 2026.
Source: PR Newswire, Pegasus/PRN Pharmacal, February 12, 2026. Link. Approximately 2.1 million dogs in the United States are estimated to be affected by seizures, making it one of the most common neurological disorders in companion animals. The condition requires lifelong management and can significantly impact the quality of life for both dogs and their families.
Leave a Reply